Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac drugs: new inotropes.

R M Kelleher

    Critical Care Nursing Clinics of North America
    |June 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Phosphodiesterase inhibitors offer a new approach to treating congestive heart failure (CHF) by improving heart function and blood vessel dilation. Further research is needed to develop oral and intravenous options for widespread clinical use.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Prognosis and quality of life after valve surgery in patients older than 75 years.

    Chest·1997
    Same author

    Dialysis in the surgical intensive care patient: a case study.

    Critical care nursing quarterly·1992
    Same author

    Prostaglandins for the control of pulmonary hypertension in the postoperative cardiac surgery patient: nursing implications.

    Critical care nursing clinics of North America·1991
    Same author

    Liver transplant program: nursing administration issues (continuing education).

    Perioperative nursing quarterly·1985
    Same author

    Milia en plaque.

    Cutis·1978

    Area of Science:

    • Pharmacology
    • Cardiology
    • Nursing

    Background:

    • Congestive heart failure (CHF) management traditionally involves inotropic, vasodilator, and diuretic agents.
    • Phosphodiesterase inhibitors represent a novel class of inotropic agents with dual inotropic and vasodilating effects.
    • Amrinone is the only approved phosphodiesterase inhibitor in the U.S., requiring specific nursing knowledge for administration and monitoring.

    Purpose of the Study:

    • To review the role of phosphodiesterase inhibitors in CHF management.
    • To highlight nursing considerations for amrinone administration.
    • To discuss ongoing research and future directions for phosphodiesterase inhibitors in CHF treatment.

    Main Methods:

    • Review of current literature on phosphodiesterase inhibitors and their application in CHF.

    Related Experiment Videos

  • Analysis of amrinone's pharmacologic profile, administration, and adverse effects.
  • Discussion of ongoing clinical trials for investigational phosphodiesterase inhibitors.

    • Main Results:

    • Amrinone is an intravenous inotropic agent with vasodilating properties used in CHF.
    • Investigational phosphodiesterase inhibitors are being studied for both oral and intravenous administration.
    • Research is exploring the impact of these agents on myocardial ischemia, mortality, and morbidity in CHF.

    Conclusions:

    • Phosphodiesterase inhibitors offer a promising therapeutic avenue for CHF.
    • Further research is essential to establish the efficacy and safety of new phosphodiesterase inhibitors for routine CHF pharmacotherapy.
    • Optimizing nursing care requires a deep understanding of CHF pathophysiology and the hemodynamic effects of these agents.